Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We're excited about our progress and the promising future that we envision for our company |
| We continue to benefit from the digital marketing expertise we've developed over the past several years, which is allowing us to effectively promote our products while prudently managing expenses |
| I'm pleased to begin by reporting that NovaBay's efforts to deepen relationships with eye care professionals is proving successful with third quarter product sales from our physician-dispensed channel growing 36% over the prior year period and increasing in each consecutive quarter so far in 2023 |
| Looking forward, we anticipate a strong finish to the year for our DERMAdoctor products |
| We're proud of our portfolio of innovative, evidence-based and clinically proven eye care, skin care and wound care products and are passionate about bringing these best-in-class products to a growing number of customers |
| Avenova Allograft is an ultra-thin, ultra-light structural tissue that has a distinct advantage as being the only optical allograft manufactured using BioStem Technologies patented six-step BioREtain process that preserves the natural integrity of the placental tissue |
| Amazon continues to be our most important sales channel, and we appreciate the opportunity to reward our current customers and attract new ones to our high-quality products |
| I'm pleased to report that we had another very strong sales event |
| We're having success with the various programs in our physician-dispensed channel |
| Our physician network helped make Avenova the number one doctor-recommended lid and lash cleanser on the market, and we are delighted to offer them these additional partnership opportunities |
| And with the Avenova Allograft, we recently introduced a compelling new product that leverages these established relationships and provides an opportunity for us to further build on this channel |
| Avenova Allograft represents a large market opportunity for NovaBay |
| Excellent |
| So we originally started just reaching out to all of the doctors that we have really good relationships with, through Avenova saying, oh, we have a new product |
| On the expense side, we continued to benefit from our expertise in digital marketing, reporting a 7% reduction in sales and marketing spend for the third quarter and a 12% decrease for the first nine months of the year |
| We believe that many users who take advantage of the special pricing offers to try our best-in-class products, subsequently become loyal, long-time customers |
| Like all of the products in our Avenova portfolio, it is science-based, high-quality and differentiated |
| We look at it all the time, and we track it fairly closely because the Avenova Spray is our highest volume and most popular product across the entire company |
| We also anticipate a sales uptick with the upcoming holiday season and will once again be offering special holiday gift sets with their KP Duty and Kakadu C collections |
| The global market for this product is estimated at more than $400 million and is expected to grow at nearly 10% annually through 2030 |
| Our ability to manage expenses has led to a 16% reduction in operating loss year-to-date versus the prior year |
| Operating loss for the first nine months of 2023 was $4.2 million, a 16% improvement from the prior year period |
| Thanks again, and have a nice day |
| Our Calm Cool + Corrected collection helps soothe and comfort irritable skin, and Total Nonscents is our ultrasensitive brightening antiperspirant |
| Well, the one sort of bright spot that I think will deliver with some certainty is the Double 11 event in China |
| Importantly, Avenova Allograft allows us to leverage our established relationships with eye care professionals as well as to continue to build out that network |
| And importantly, we're on a strategy to conserve cash and extend our cash runway, which is especially important under the current challenging market conditions |
| We've made it a priority to focus on expense management and cash preservation this year with an eye towards extending our cash runway in this challenging market environment |
| On our last quarterly conference call, I spoke about our new strategy to increase sales of our most popular DERMAdoctor products in our most efficient sales channels |
| We love this |
| Statement |
|---|
| In particular, there is uncertainty about circumstances beyond the company's control that impact the broader economy |
| As a final note about our eye care franchise, some of you have asked about recent FDA warnings regarding the use of eye drops from certain foreign manufacturers and some products being recalled and removed from store shops |
| Can you just remind me whether or not you'll be expanding product lines or adding product lines? And then I'm also curious, during the quarter, revenue was a little muted |
| Not only is this channel important as a standalone revenue source, it also creates a halo effect around our direct-to-consumer sales channel by establishing Avenova as a doctor recommended brand |
| So and dry eye is a chronic problem |
| Total expense -- total operating loss for the third quarter of 2023 was $1.1 million compared with an operating loss of $0.5 million for the prior year, with the increase due primarily to lower margins and higher G&A expenses, partially offset by lower sales and marketing expenses |
| The net loss for the third quarter of 2023 was $1.7 million or $0.37 per share |
| We regularly hear from eye care professionals that dry eye is a major concern for many of their patients |
| Gross margin on net product revenue for the third quarter was 56% versus 62% for the third quarter of 2022, with the decrease primarily due to product and channel mix |
| This compares with a net loss for the third quarter of 2022 of $5.8 million or $3.61 per share, which included the noncash items I just mentioned |
| Total operating expenses for the first nine months of 2023 decreased 7% to $10.3 million compared with the prior year |
| The net loss for the first nine months of 2023 was $7.5 million or $2.27 per share, which compares with a net loss for the first nine months of 2022 of $8.1 million or $5.32 per share |
| So we don't have any product development planned because new product development is uncertain and it's also expensive |
| I'd like to assure you that Avenova Spray and Avenova Lubricant Eye Drops are made in the United States and are unaffected by the FDA warnings and recalls |
| And I know based on our models, we've seen a bit of seasonality like you mentioned and with heavier revenue or greater revenue in the fourth quarter |
Please consider a small donation if you think this website provides you with relevant information